Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients

European Journal of Neurology

Volumn 19, Issue 5, 2012, Pages 788-792

  Anand, A ^a   Gupta, P K ^a   Sharma, N K ^a   Prabhakar, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Amyotrophic lateral sclerosis; Serum; Soluble vascular endothelial growth factor receptor 1; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INDIA; MALE; NERVE DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REGULATORY SEQUENCE; SURVIVAL TIME;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84859823909     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03548.x     Document Type: Article

References (10)

1. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-417.
2. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8: 85-92.
3. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood retinal barrier. Hum Gene Ther 2003; 14: 129-141.
4. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90: 10705-10709.
5. Gupta PK, Prabhakar S, Sharma S, Anand A. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in Amyotrophic Lateral Sclerosis (ALS) patients. J Neuroinflammation 2011; 8: 47.
6. Nalini A, Thennarasu K, Gourie-Devi M, Shenoy S, Kulshreshtha D. Clinical characteristics and survival pattern of 1, 153 patients with amyotrophic lateral sclerosis: experience over 30years from India. J Neurol Sci 2008; 272: 60-70.
7. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002; 59: 280-282.
8. Sun Y, Jin K, Xie L, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111: 1843-1851.
9. Zheng C, Sköld MK, Li J, Nennesmo I, Fadeel B, Henter JI. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun 2007; 363: 989-993.
10. Vinish M, Prabhakar S, Khullar M, Verma I, Anand A. Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India. J Neurol Neurosurg Psychiatry 2010; 81: 166-170.